HPV vaccination and allocative efficiency: regional analysis of the costs and benefits with the bivalent AS04-adjuvanted vaccine, from the perspective of public health, for the prevention of cervical cancer and its pre-cancerous lesions. FE [Internet]. 2012 Nov. 20 [cited 2025 Oct. 29];13(2S):3-15. Available from: https://journals.seedstm.com/index.php/FE/article/view/449